While the emergence of the covalent KRASG12C inhibitor being developed by Amgen has garnered enthusiasm, there remains a pressing need for therapeutic strategies targeted at cancers driven by other KRAS mutations, especially given the dismal outcomes for patients with cancers driven by mutations in KRAS codon 1354,55. Here, KRAS is linked to cancer.